Publication
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Authors not recorded
Breast Cancer Res2008PMID 18371219PMC2397526stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugFAC Regimencivic_curation1.00
- drugFEC Regimencivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA E542Kcivic_curation1.00
- variantPIK3CA E545Kcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 18371219
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA E542K + PIK3CA E545K + PIK3CA H1047R1 | ||||||||
| FAC Regimen + FEC RegimenSubstitutes | Malignant Breast Neoplasm | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6191This study of 140 patients with stage II-III breast cancer assessed the response of patients with PIK3CA mutations to 6 months of preoperative chemotherapy. Exons 1, 9, and 20 of PIK3CA were screened… (full text at CIViC) PMID 18371219 · Liedtke et al., 2008 · Open in CIViC | civic |